Status:
COMPLETED
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
Lead Sponsor:
European Institute of Oncology
Conditions:
Pancreatic Neuroendocrine Tumour Metastatic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Everolimus represents an approved therapy for patients with advanced well/moderately differentiated pancreatic NETs. Although some patients could benefit from this drug in terms of long-term tumor gro...
Detailed Description
• Background:: Everolimus has been reported to be effective compared with placebo in well/moderately differentiated pancreatic NETs in terms of progression-free survival (PFS) improvement. However, a ...
Eligibility Criteria
Inclusion
- Histological diagnosis of metastatic well/moderately differentiated pancreatic neuroendocrine tumor
- Patient incoming to be treated with everolimus outside clinical trials or within a clinical trial that permits the concurrent inclusion in an ancillary trial
- Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Exclusion
- Patients with poorly differentiated neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid, small cell carcinoma, Merkel cell carcinoma.
- Patients with pancreatic NETs not eligible to be treated with everolimus
- Patients with ongoing everolimus treatment
- Prior therapy with mTOR inhibitors
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2018
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT02305810
Start Date
September 1 2013
End Date
June 1 2018
Last Update
November 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute of Oncology
Milan, Italy